HRS-4729 / Jiangsu Hengrui Pharma - LARVOL DELTA

Safety, tolerability, pharmacokinetics, and pharmacodynamics of HRS-4729, a novel GLP-1/GIP/glucagon triple-receptor agonist: a randomised, double-blind, placebo-controlled Phase 1 study (EASD 2026) - P1 | "In the multiple ascending dose (MAD) part, adults living with obesity (BMI 28-40 kg/m 2 ) and without diabetes were randomized to receive weekly HRS-4729 (1mg fixed dose; 4, 8, or 12 mg with titration), placebo, or weekly ribupatide injection (4 mg titration) for 12 weeks. HRS-4729 showed an acceptable safety profile similar to other incretin-based medications, and the PK data supports once-weekly administration. These findings, together with the favorable weight loss effect, support further development of HRS-4729 in obesity."

Clinical • First-in-human • Late-breaking abstract • P1 data • PK/PD data • Diabetes • Metabolic Disorders • Obesity

A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis (clinicaltrials.gov) - P2 | N=160 | Recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis

A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity (clinicaltrials.gov) - P2 | N=252 | Not yet recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

New P2 trial • Genetic Disorders • Obesity

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects (clinicaltrials.gov) - P1 | N=102 | Completed | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis (clinicaltrials.gov) - P2 | N=160 | Not yet recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

New P2 trial • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects (clinicaltrials.gov) - P1 | N=102 | Completed | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Trial completion date: Dec 2025 ➔ Mar 2026 | Trial primary completion date: Dec 2025 ➔ Mar 2026 | Recruiting ➔ Completed

Trial completion • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

Hengrui Class 1 innovative drug GLP-1R/GIPR/GCGR tri-receptor agonist HRS-4729 for metabolic-associated fatty liver disease/metabolic-related steatohepatitis approved clinical [Google translation] (Jiangsu Hengrui Press Release)

New trial • Metabolic Dysfunction-Associated Steatohepatitis